Publicaciones (111) Publicaciones de RICARDO CABALLERO COLLADO

2024

  1. Coexistent HCN4 and GATA5 Rare Variants and Atrial Fibrillation in a Large Spanish Family

    Canadian Journal of Cardiology, Vol. 40, Núm. 7, pp. 1270-1280

  2. Drug-induced atrial fibrillation. A narrative review of a forgotten adverse effect

    Pharmacological Research, Vol. 200

  3. Reply to Benndorff and DiFrancesco: Reliable human HCN4 single-channel recordings using the cell-attached configuration in expression systems

    Proceedings of the National Academy of Sciences of the United States of America

  4. Variable Penetrance and Expressivity of a Rare Pore Loss-of-Function Mutation (p.L889V) of Nav1.5 Channels in Three Spanish Families

    International Journal of Molecular Sciences, Vol. 25, Núm. 9

2023

  1. A Cantú syndrome mutation produces dual effects on KATP channels by disrupting ankyrin B regulation

    The Journal of general physiology, Vol. 155, Núm. 1

  2. A gain-of-function HCN4 mutant in the HCN domain is responsible for inappropriate sinus tachycardia in a Spanish family

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 120

  3. Sex and gender differences in the treatment of arterial hypertension

    Expert Review of Clinical Pharmacology, Vol. 16, Núm. 4, pp. 329-347

2022

  1. Cancer Chemotherapy-Induced Sinus Bradycardia: A Narrative Review of a Forgotten Adverse Effect of Cardiotoxicity

    Drug Safety, Vol. 45, Núm. 2, pp. 101-126

  2. Empagliflozin and Dapagliflozin Increase Na+ and Inward Rectifier K+ Current Densities in Human Cardiomyocytes Derived from Induced Pluripotent Stem Cells (hiPSC-CMs)

    Cells, Vol. 11, Núm. 23

  3. Hypertrophic cardiomyopathy: an up-to-date snapshot of the clinical drug development pipeline

    Expert Opinion on Investigational Drugs

  4. Regulation of cardiac ion channels by transcription factors: Looking for new opportunities of druggable targets for the treatment of arrhythmias

    Biochemical Pharmacology, Vol. 204

  5. Sex-related differences in the pharmacological treatment of heart failure

    Pharmacology and Therapeutics, Vol. 229

  6. Tbx5 variants disrupt Nav1.5 function differently in patients diagnosed with Brugada or Long QT Syndrome

    Cardiovascular research, Vol. 118, Núm. 4, pp. 1046-1060

2021

  1. A rare HCN4 variant with combined sinus bradycardia, left atrial dilatation, and hypertrabeculation/left ventricular noncompaction phenotype

    Revista Espanola de Cardiologia, Vol. 74, Núm. 9, pp. 781-789

  2. Los fármacos, los canales iónicos y las arritmias cardiacas: retorno a Ítaca

    Actualidad en farmacología y terapéutica, Vol. 19, Núm. 3, pp. 142-145

  3. The pharmacotherapeutic management of hyperkalemia in patients with cardiovascular disease

    Expert Opinion on Pharmacotherapy, Vol. 22, Núm. 10, pp. 1319-1341

  4. Zfhx3 transcription factor represses the expression of SCN5A gene and decreases sodium current density (Ina)

    International Journal of Molecular Sciences, Vol. 22, Núm. 23

2020

  1. The p.P888L SAP97 polymorphism increases the transient outward current (Ito,f) and abbreviates the action potential duration and the QT interval

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. Digenic Heterozigosity in SCN5A and CACNA1C Explains the Variable Expressivity of the Long QT Phenotype in a Spanish Family

    Revista Espanola de Cardiologia, Vol. 72, Núm. 4, pp. 324-332

2018

  1. Brugada syndrome trafficking-defective Nav1.5 channels can trap cardiac Kir2.1/2.2 channels

    JCI insight, Vol. 3, Núm. 18